Effect of Buprenorphine on reduction of withdrawal symptoms, depression and suicidal thoughts

Comparing the effect of different doses of Buprenorphine (32 mg- 64 mg- 96 mg) on the reduction of opioid withdrawal symptoms and reduction of their depression and suicidal thoughts

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016071325160N4

Enrollment

Registered

2017-01-24

Start date

2016-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid dependency. Mental and behavioural disorders due to use of opioids

Interventions

Intervention 1: 32 mg buprenorphine is given as a single dose to patients and evaluated withdrawal symptoms, depression and suicidal thoughts for two weeks. Intervention 2: 64 mg buprenorphine is

Treatment - Drugs

32 mg buprenorphine is given as a single dose to patients and evaluated withdrawal symptoms, depression and suicidal thoughts for two weeks.

64 mg buprenorphine is given as a single dose to patients and evaluated withdrawal symptoms, depression and suicidal thoughts for two weeks.

96 mg buprenorphine is given as a single dose to patients and evaluated withdrawal symptoms, depression and suicidal thoughts for two weeks.

Eligibility

Sex/Gender

Male

Age

16 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria:age between 16 to 60 y/o; informed consent;Opioid dependence Exclusion criteria:Patients unwilling to participate at beginning or during the study; use of other substances except Opioid as of the main substance.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Reduction of depression in opiod dependents and find the best choice. Timepoint: before the first dose and first day to 14 days. Method of measurement: interview and questionnaires.;Reduction of withdrawal symptoms in opiod dependents and find the best choice. Timepoint: before the first dose and first day to 14 days. Method of measurement: interview and questionnaire.;Reduction of suicidal thouhgts in opiod dependents and find the best choice. Timepoint: before the first dose and first day to 14 days. Method of measurement: interview and questionnaires.	—

Measure

Time frame

Reduction of depression in opiod dependents and find the best choice. Timepoint: before the first dose and first day to 14 days. Method of measurement: interview and questionnaires.;Reduction of withdrawal symptoms in opiod dependents and find the best choice. Timepoint: before the first dose and first day to 14 days. Method of measurement: interview and questionnaire.;Reduction of suicidal thouhgts in opiod dependents and find the best choice. Timepoint: before the first dose and first day to 14 days. Method of measurement: interview and questionnaires.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJamshid Ahmadi M.D.

Shiraz University of Medical Sciences

jamshid_ahmadi@yahoo.com+98 71 3646 1511

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026